Inhaled drug developer Transpire Bio announced that it has hired Ewan Livesey as Head of Business Development. Livesey has more than 30 years experience in business and corporate development and has served in a number of executive positions in pharmaceutical companies, including Apotex, Lupin, Glenmark, and IVAX.
Within the past year, Transpire has announced that it had acquired rights to develop Suzhou Intragrand Pharma’s ITG-1052 PDE4 inhibitor as an inhaled therapy for IPF; initiated a Phase 1 trial of an inhaled cannabidiol formulation; and submitted an ANDA for a generic version of Trelegy Ellipta DPI.
Transpire CEO Xian-Ming Zeng commented, “As Transpire Bio continues to progress its pipeline of complex generics and innovative medicines, we are strengthening our business development expertise to expand our focus on in-license, out-license and co-development opportunities that align with our business strategy. We are thrilled to welcome Mr. Livesey as Head of Business Development. He brings extensive expertise in all areas of business development.”
Livesey said, “It is an honor to join Transpire Bio as Head of Business Development. I look forward to advancing the company’s strategic partnerships and supporting the continued advancement of our growing pipeline. I am excited to be joining Transpire Bio at a pivotal time for the company as we expand our opportunities and build momentum across our innovative programs.”
Read the Transpire Bio press release
